New dosing option for AZ’s Imfinzi approved in the EU and UK

In AZ’s recent third quarter results, the British drugmaker reported that its oncology franchise had grown by 24% to $8.15bn – with Imfinzi accounting for $1.48bn of that amount.

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to defend its franchise with its new generation 20-valent pneumococcal vaccine.

Novartis receives FDA breakthrough therapy designation for rare disease med

Alexion’s other long-acting C5 inhibitor, Ultomiris (ravulizumab‑cwvz) is also approved in these indications, making the franchise Novartis potential main competitors.

CONNECT Customer Engagement Framework

Through delivery of the programme throughout Europe (and now beyond), CONNECT has been able to harmonise, for the first time at Sanofi Genzyme, the customer-facing approach across brands, franchises, countries

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]